@article{072300998c924121a545fdfb46bc8886,
title = "Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study",
abstract = "Objectives We explored the effects of B-cell directed therapy in subjects at risk of developing autoantibodypositive rheumatoid arthritis (RA), who never experienced inflammatory arthritis before, and explored biomarkers predictive of arthritis development.Methods Individuals positive for both anti-citrullinated peptide antibodies and rheumatoid factor but without arthritis were included in a randomised, double-blind, placebo-controlled study to receive a single infusion of 1000 mg rituximab or placebo.Results Eighty-one individuals received treatment and were followed up for a mean of 29.0 (0-54) months, during which 30/81 (37%) individuals developed arthritis. The observed risk of developing arthritis in the placebo-treated group was 40%, which was decreased by 55% (HR 0.45, 95% CI 0.154 to 1.322) in the rituximab-treated group at 12 months. Rituximab treatment caused a delay in arthritis development of 12 months compared with placebo treatment at the point when 25% of the subjects had developed arthritis (pConclusions A single infusion of 1000 mg rituximab significantly delays the development of arthritis in subjects at risk of developing RA, providing evidence for the pathogenetic role of B cells in the earliest, prearthritis stage of autoantibody positive RA.",
keywords = "SEROPOSITIVE ARTHRALGIA, TARGETED THERAPY, RISK-FACTORS, DISEASE, RITUXIMAB, AUTOANTIBODIES, METHOTREXATE, INDIVIDUALS, INDUCTION, EFFICACY",
author = "Gerlag, {Danielle M.} and Mary Safy and Maijer, {Karen I.} and Tang, {Man Wai} and Tas, {Sander W.} and Starmans-Kool, {Mirian J. F.} and {van Tubergen}, Astrid and Matthijs Janssen and {de Hair}, Maria and Monika Hansson and {de Vries}, Niek and Zwinderman, {Aeilko H.} and Tak, {Paul P.}",
note = "Funding Information: Funding was received from the Dutch Arthritis Foundation (grant number 11-1-407); Netherlands Organisation for Health Research and Development (ZonMw; grant number 200310003); European Union Seventh Framework Programme (project EuroTEAM; grant number FP7-HEALTHF2-2012-305549); IMI EU-funded project BeTheCure (grant number 115142) Funding Information: of GlaxosmithKline, UK. GlaxosmithKline was not involved in the design and/or execution of the study. ndV reports grants from abbVie, Janssen Biologics, ergomed Clinical Research, GlaxosmithKline, Pfizer, Boehringer ingelheim, and Roche, as well as personal fees from MsD, UCB, Janssen, non-financial support from Roche, personal fees and non-financial support from Pfizer, all outside the submitted work. in addition, ndV has a patent method for determining the risk of developing arthritis pending. Ms reports a research grant from astraZeneca (received in august 2015). astraZeneca was not involved in this study. Funding Information: Funding Funding was received from the Dutch arthritis Foundation (grant number 11-1-407); netherlands Organisation for Health Research and Development (ZonMw; grant number 200310003); european Union seventh Framework Programme (project euroTeaM; grant number FP7-HealTHF2-2012-305549); iMi eU-funded project BeTheCure (grant number 115142). Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2019",
month = feb,
doi = "10.1136/annrheumdis-2017-212763",
language = "English",
volume = "78",
pages = "179--185",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",
}